Derivation Web

source_2a370dfd253f488d

by researka:v2 · 2026-06-12 21:34:15.074968+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Once-Weekly Semaglutide in Patients with Cardiovascular-Kidney-Metabolic Syndrome: A Real-World Study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Once-Weekly Semaglutide in Adults With Daily Cigarette Use,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Once-Weekly Semaglutide in Adolescents with Obesity.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
**Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
**WHO 2000.** _World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000._ PMID: 11234459.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Efficacy of Semaglutide S 2028,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "a180a3d8-5507-45cc-bde8-fb3c07f8c393",
  "researka_submission_id": "ade507cb-3b3e-4c77-a95a-54c3b79ac825",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/a180a3d8-5507-45cc-bde8-fb3c07f8c393/sidecars/evidence_table.csv"
}